

FDA New Drug Approvals July,2018

Brand name	Active Ingredient	Dosage form	Company	Treatment for	US FDA Approval Date
Mulpleta	lusutrombopag	Oral	SHIONOGI INC	To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure	31/7/2018
Omegaven	fish oil triglycerides	injectable emulsion, for intravenous use	FRESENIUS KABI USA	As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis	27/7/2018
Orilissa	elagolix sodium	tablets, for oral use	ABBVIE INC	For the management of moderate to severe pain associated with endometriosis	23/7/2018
Krintafel	tafenoquine	tablets, for oral use	GLAXOSMITHKLINE	For the radical cure (prevention of relapse) of Plasmodium vivax malaria	20/7/2018
Tibsovo	ivosidenib	tablets, for oral use	AGIOS PHARMACEUTICALS INC	To treat patients with relapsed or refractory acute myeloid leukaemia	20/7/2018
TPOXX	tecovirimat	capsules, for oral use	SIGA TECHNOLOGIES INC	To treat smallpox	13/7/2018

<https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm592464.htm>

For any Feedback or suggestion mail at: info@pharmastate.com

Weblink – <https://pharmastate.com/>

Applink- <https://goo.gl/mS8Lr7>

Disclaimer: The information in this presentation was compiled from sources believed to be reliable for informational purposes only. We do not guarantee the accuracy of this information or any results and further assume no liability in connection with this publication, including any information, methods or safety suggestions contained herein. For the latest updates pertaining to this compilation visit the relevant website.